Day One Biopharmaceuticals

What a night! It was thrilling to witness the response to the film, "Seeing a Different Future", about a small group of families, doctors, and drug developers whose dedication and partnership brought to life a treatment for children with brain cancer. We are grateful to every individual, organization, and company that played a role in this powerful story of collaboration. Watch the documentary here: https://xmrrwallet.com/cmx.plnkd.in/eFufm_RJ

Our CEO Jeremy Bender recently had the pleasure of joining Biotech2050 to reflect on the journey we’ve been on at Day One Biopharmaceuticals—from a bold vision to prioritize pediatric oncology, to launching our first FDA-approved medicine. Jeremy discussed what it’s been like stepping into the CEO role for the first time, and lessons around leadership, focus, and staying true to your mission. Listen to hear more about how small biotechs can drive big impact and best practices for leading a resilient organization through uncertain times. Thank you to Rahul Chaturvedi for the thought-provoking conversation around growth and innovation. http://xmrrwallet.com/cmx.pbit.ly/3UpaFWC

Our mission is what drives us: you can feel it in every Zoom meeting, hallway huddle, or all-company meeting. At Day One, we're here to deliver for patients and we've built a team that shows up with urgency and purpose every single day. If you're looking for purpose-driven work in a culture rooted in impact, connection, and collaboration; we'd love to hear from you. See our open roles here: https://xmrrwallet.com/cmx.pbit.ly/40GjE8y

Join us at the 5th Chief Patient Officer conference, July 22-23, in Boston! Day One's Christa Kerkorian will be co-presenting "Advance Research and Development through Multi-Stakeholder Collaboration". Register here today with the speaker code below: https://xmrrwallet.com/cmx.pbit.ly/4esWI3n

We're hiring! Join us in our mission to develop new therapies for patients of all ages with life threatening diseases. We’re looking for a driven, collaborative, and experienced Medical Director to provide clinical and scientific leadership across our early and late-stage clinical trials. If you’re a physician or physician-scientist with a passion for oncology drug development, we want to hear from you. Learn more and apply today: https://xmrrwallet.com/cmx.pbit.ly/3GEevb8

We’re very excited for the first screening of 𝑺𝒆𝒆𝒊𝒏𝒈 𝒂 𝑫𝒊𝒇𝒇𝒆𝒓𝒆𝒏𝒕 𝑭𝒖𝒕𝒖𝒓𝒆 in Boston on July 23. Dedicated to the children and families around the world facing a pediatric cancer diagnosis, the documentary tells the story of how a community came together to advance research and drug development in children with brain cancer. If you are in Boston, learn more about the screening here: https://xmrrwallet.com/cmx.pbit.ly/45DxH2O

At Day One, we believe that every day matters, especially day one of a cancer diagnosis. Our mission is to develop targeted therapies that bring hope and better outcomes to children and people of all ages facing cancer. Our name was inspired by "The Day One Talk," a life-altering moment for both children and their families. "We were trying to figure out what to name the company. I thought about what it was that we were trying to do, and at the end of the day I realized we wanted to have new medicines available for physicians to talk about at The Day One talk, so we called it Day One Biopharmaceuticals." Dr. Sam Blackman, M.D., Co-founder of Day One. Learn more: https://xmrrwallet.com/cmx.pbit.ly/4gsrd8W

We’re honored to be recognized by California Life Sciences (CLS) for our active engagement as part of this incredible community. We believe innovation in life sciences happens when we come together, collaborate across the ecosystem, and support one another. Thank you to the California Life Sciences (CLS) team for this recognition and to our employees whose passion, purpose, and urgency, make our contributions possible.

In a new article published by Immuno-Oncology 360° Community News, Day One's Chief Medical Officer, Elly Barry, shares critical insights on how the regulatory landscape for pediatric oncology is shifting, and why early planning and academic collaboration are now more critical than ever. Read the article here: https://xmrrwallet.com/cmx.pbit.ly/3ToUh7W

We're thrilled to announce that Michael Vasconcelles, M.D., has joined Day One as Head of Research & Development (R&D). Mike brings more than 25 years of experience in oncology research and development as an academic hematologist/oncologist and as an industry leader in large pharmaceutical, health technology, and emerging biotechnology companies. Mike will be instrumental in helping to drive innovative medical and scientific strategies to support OJEMDA’s growth while also continuing to build our pipeline of first- or best-in-class medicines for patients of all ages with life-threatening diseases. Read more: https://xmrrwallet.com/cmx.pbit.ly/3Zq67Cj